Vol. 19/No. 23 | OncologyLive

Progress and Challenges Mark the Myelofibrosis Landscape

December 12, 2018

A growing understanding about the underlying biology of myelofibrosis has helped improve the diagnosis and treatment of the disease during the past decade and is paving the way for further advancements.

Robust Future Ahead for Stem Cell Transplants

December 06, 2018

Although many new drugs have been introduced for treating patients with hematologic malignancies, stem cell transplantation remains a vital part of the therapeutic paradigm, particularly for multiple myeloma and non-Hodgkin lymphoma.

Investigators Seek Expanded Use of Checkpoint Inhibitors in RCC

December 05, 2018

In contrast to the wide array of available therapies in the metastatic setting of renal cell carcinoma, in patients with localized disease, the results of trials investigating adjuvant systemic therapy after nephrectomy have so far been underwhelming.

Novel Antibody-Drug Conjugate Enters Phase III Trial for Metastatic TNBC

December 04, 2018

Investigators are optimistic about sacituzumab govitecan (IMMU-132), an antibody–drug conjugate that delivers the chemotherapy metabolite SN-38 to tumor cells expressing the TROP-2 receptor, for patients with relapsed/refractory TNBC.